Title: Zuidex versus Contigen for Stress Urinary Incontinence. Date: May 30, 2007

Size: px
Start display at page:

Download "Title: Zuidex versus Contigen for Stress Urinary Incontinence. Date: May 30, 2007"

Transcription

1 Title: Zuidex versus Contigen for Stress Urinary Incontinence Date: May 30, 2007 Context and policy issues: Stress urinary incontinence (SUI) is the involuntary leakage of urine during exercise or movements such as coughing, laughing, or sneezing. 1 These activities cause increases in intra-abdominal pressure that lead to involuntary leakage of urine in the absence of bladder contraction. SUI is usually caused by weak or damaged muscles and connective tissues of the pelvic floor, or by weakness of the urethral sphincter itself. 1 SUI patients can be divided into two groups: those with urethral hypermobility and those with intrinsic sphincteric deficiency (ISD) where there is damage to the urethral sphincter arising with prior surgery, spina bifida, or childbirth. 2 An estimated one in three women may experience urinary stress incontinence at some point in their lives. It can happen at any age, although it is more common in women between the ages of 35 and Urinary stress incontinence is rare in men, and is usually a result of injury or prostate surgery. 2 One source states that in the United States, 25 million individuals suffer from SUI (85% are female and 56% are less than 65 years of age). 3 An Ontario survey found that half of the women 45 years old and older who attended two family medicine clinics presented with urinary incontinence. 4 Approximately a third of these reported SUI. Typically, first-line treatment is conservative and includes lifestyle adjustments to reduce pressure on the bladder (e.g. smoking cessation, weight control, and fluid intake), pelvic floor exercises, electrical stimulation, or biofeedback. 2 If the condition does not improve, surgical options for women include bladder neck suspension, implantation of an artificial sphincter or sacral nerve simulator, tension-free vaginal tape, or traditional suburethral slings. 2 Due to limited evidence of efficacy for medications (including oral/vaginal estrogen in postmenopausal women, imipramine, and duloxetine), surgery is usually recommended over pharmacologic therapy. 2 However, open surgery means hospitalization for a few days and increased risk for serious complications including bleeding; surgical injury; infection; cardiac, thromboembolic, or pulmonary events; and urinary retention. 2 Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information on available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.

2 Periurethral injections of bulking agents offer an alternative to surgery for SUI associated with ISD when lifestyle modifications and pelvic strengthening techniques, or prior surgery fail to adequately control symptoms. 5 Most surgeons no longer use bulking agents for hypermobility-related stress incontinence because of the profusion of new synthetic slings that are more effective and durable. 1 Non-absorbable bulking agents include Macroplastique (silicone particles), Polytef (polytetrafluoroethylene), Durasphere (carbon-coated beads), and Coaptite (calcium hydroxylapatite). 5 Absorbable bulking agents include Contigen (glutaraldehyde cross-linked bovine collagen), Uryx (ethylene vinyl alcohol coplymer), Zuidex (dextranomer/hyaluronic acid), and autologous fat. 5 Bulking agents act to increase tissue bulk around the urethra, thereby increasing resistance to the outflow of urine. 5 Periurethral injection of bulking agents is administered in an outpatient procedure under local anesthesia. 1 Therefore, the procedure is associated with a shorter recovery time and lower risk for complications than surgery. 1 Transient urinary retention, hematuria, sterile abscess formation, irritative voiding symptoms and urinary tract infection are all common treatment-related adverse effects. 1 These usually resolve spontaneously within a few days or with appropriate antibiotic treatment or catheterization. While autologous fat, Macroplastique, Contigen, Durasphere and Polytef have all demonstrated positive short-term results, none have met both criteria for success (remaining efficacious over time) and maintaining a low side-effect profile. Use of Polytef has been limited due to evidence of granuloma formation and migration to other tissues 3. Macroplastique has also become unpopular due the potential for an autoimmune reaction and possible migration to other organs. 3 Autologous fat is difficult to harvest, is reabsorbed from the injection site at an unacceptably high rate, and has been associated with a rare complication of fat embolization. 3 Durasphere beads can be cumbersome to inject and sterile abscess formation has been reported. 3 Although experience with Contigen indicates a good safety profile (there is no evidence the implant causes an inflammatory reaction or granuloma formation, and it is not known to migrate), resorption occurs over time decreasing long-term efficacy and repeat injections are often required. 5 Results from several observational trials of Contigen indicate that early results are generally good with success rates of 72% to 100%. 5 Longer-term results with follow-up of up to 4 years of women who are cured or improved vary from 57% to 94%. 5 While Contigen is currently the most widely used bulking agent, the optimal timing and frequency of injection have not been established. 1 In addition, preoperative allergy testing one month prior to the procedure is necessary since 1-4% of women report skin hypersensitivity. 5 Zuidex administered via an implacer device is one of the newest bulking agents available for treatment of SUI. It was licensed by Health Canada (classified as a medical device) in Zuidex is a highly viscous gel of dextranomer microspheres and nonanimal stabilized hyaluronic acid. 6 The gel has no immunogenic properties, and has not been shown to migrate to different organs after submucosal injection. 5 The implacer device has been developed to allow reproducible urethral injection by guiding the gel to the appropriate area. 7 As a relatively new treatment, considering the overall impact of Zuidex versus Contigen for stress urinary incontinence 2

3 Zuidex in terms of clinical outcome, long-term safety and efficacy, and cost is necessary in order to make a decision regarding implementation. The available evidence for the clinical and cost-effectiveness of Zuidex in comparison to Contigen will be discussed. Research questions: What is the comparative clinical effectiveness (benefit and harm) and cost-effectiveness of Zuidex and Contigen for urinary stress incontinence? Methods: A literature search was conducted on key health technology assessment resources, including PubMed, The Cochrane Library (Issue 2, 2007), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI s HTAIS database, EuroScan, international HTA agencies, and a limited Internet search. Bibliographies of relevant sources were also scanned to identify further evidence. Results include English language publications from 2002 to date. Links to online full-text references or abstracts are provided where available. Summary of findings: No health technology assessments were identified, nor were any published, randomized controlled trials found that examine the safety and efficacy of Zuidex in comparison to Contigen or other treatments for SUI (though a multicentre trial is currently underway). A 2003 Cochrane Collaboration systematic review examined the effects of periurethral injection therapy for the treatment of urinary incontinence in women. 8 Seven randomized and quasi-randomised controlled trials were identified where at least one management arm involved periurethral injection therapy (including autologous fat, Macroplastique, Durasphere, Coaptite, Uryx, and Contigen). No studies could be located that compared periurethral injection to conservative therapy (lifestyle modifications, pelvic floor exercises, electrical stimulation, biofeedback, or pharmacotherapy). No studies examining Zuidex were included. Due to significant heterogeneity in study design and limited available data, a meta-analysis could not be performed. Four studies directly comparing injection of different bulking agents found that Macroplastique and Durasphere produced equivalent improvement at 12 months to Contigen. One multicentre randomized controlled trial was retrieved that compared surgery (Burch colposuspension, sling, bladder neck suspension) to Contigen injection in 133 women with pure or mixed stress urinary incontinence. 9 Patients who received Contigen were treated on an outpatient basis under local anesthesia, and were permitted to have up to three injections at one-month intervals before the treatment was considered a failure. Success was defined as having a dry 24-hour pad test and no additional interventions after 12 months. The success rate at 12 months after Contigen injection was significantly lower than that after surgery (53.1% versus 72.2%; p=0.01). However, the general and disease-specific quality-of-life scores were not significantly different (p=0.306) between the two groups at 12 months. Women treated by surgery were, on average, more satisfied (79.6%) than those treated by Contigen injection (67.2%), but the difference was not statistically significant (p=0.228). Finally, complications were significantly less frequent and severe with Contigen injection (36 Zuidex versus Contigen for stress urinary incontinence 3

4 events in 23 subjects versus 84 events in 34 subjects for surgery; p=0.03). In addition to greater postoperative pain, surgery was associated with more events of complete retention greater 48 hours after surgery (9 versus 1; p=0.001, transient difficulty voiding (24 versus 11; p=0.02), and urinary infection (4 versus 0; p=0.002). Rates of transient hematuria did not differ between the two treatment groups (8 events each). The authors argued that although therapy with Contigen produced a 19% lower success rate at 12 months than that of surgery, this result should be balanced with similar changes in quality of life and satisfaction in both groups as well as the number and severity of complications. Longer follow-up is necessary to ensure that the difference in success rate at one year remains stable with time. While no randomized controlled trials assessing Zuidex have yet been published, several observational trials provide some evidence for efficacy and long-term safety. The first study of transurethral endoscopically administered Zuidex involved 20 patients with SUI, 6 of whom had previously received surgery for SUI or prolapse. 10 Safety was assessed by infection rate, need for catheterization, residual urine, and dysuria. Treatment efficacy was estimated objectively by a short-term pad test with standardized physical exercise and a 48-hour pad test. Objective cure was defined as leakage less than 8g per 24 hours in the 48-hour pad test or less than 1g in the short-term pad test. Objective improvement was considered to be a reduction of incontinence by 50% in the 48-h pad test and/or in the short-term pad test. At 3-7 months follow-up, an objective cure or improvement rate of 85% was observed (45% and 40%, respectively). Four patients required catheterization due to voiding problems during the first 24 hours postoperatively. One patient reported urinary retention 14 days postoperatively. No urinary tract infections or local infections were detected. Seven patients experienced urgency and increased frequency of micturition within one month after treatment. In five of these cases, symptoms resolved with anticholinergic drugs within 3 months and in the other two patients, symptoms persisted after 6 months. In a follow-up study, only 25% of patients reported recurrence incontinence after a mean follow-up of 6.5 years and no long-term adverse effects were reported. 11 Administration of Zuidex via the implacer device has been investigated in two European studies, both involving surgery-naïve patients in whom ISD or hypermobility was not determined. 12,13 In a 36-month pilot study (n=42), significant improvements in median urine leakage (with jumping jacks or vigorous coughs) and number of incontinence episodes per 24 hours were observed at 12 months (both p< versus baseline). 12 Significant improvements over baseline were also noted in quality of life measures. 14 No significant differences in median urine leakage occurred during a 24-month followup of 20 participants and no further treatment-related adverse events or complications were reported. 15 In the second open multicentre study (n=142), a positive response to treatment was defined as a reduction in urine leakage as a result of an exercise routine of at least 50% relative to baseline. 13 The protocol consisted of an initial injection followed by another at 8 weeks if required. A total of 61 patients (43%) underwent the second injection. The response rate was 78% and 77% of patients at 12 weeks and 12 months, respectively. After 12 months, significant reductions (all comparisons P<0.001 versus baseline) were observed in median urine leakage (93%), 24-hour pad weight test Zuidex versus Contigen for stress urinary incontinence 4

5 leakage (89%) and the number of incontinence episodes per 24 hours (67%). Significant improvements were also noted in global assessment of incontinence problems and quality of life over 12 months. Treatment-related adverse events occurred in 81 (57%) of patients. Urinary retention was the most common with 29 occurrences (14 of which were classified as serious requiring hospitalization and routine catheterization) and all resolved during the study (median duration 3 days). Other treatment-related adverse effects included urinary tract infection (17 occurrences), micturition urgency (17 occurrences), dysuria (11 occurrences), injection site reaction (11 occurrences), vaginal discomfort (10 occurrences), cystitis (8 occurrences), injection site pain (6 occurrences), injection site infection (3 occurrences, all classified as serious), fever (6 occurrences), and micturition frequency (5 occurrences). In addition, an injection site pseudocyst was reported in six patients, one of which was classified as serious. Four of these were drained and all six resolved (median duration days). The lack of significant deterioration in urinary leakage during the first 12 months after treatment in this study suggests that patients initially responding to treatment with Zuidex may continue to benefit for an extended period of time. A recent case report indicates that there is a risk of granuloma developing locally secondary to Zuidex injection. 16 Larger long-term studies are still needed to complete the safety profile of Zuidex. An ongoing randomized double-blind multicentre trial is being conducted in women with SUI comparing the safety and efficacy of Zuidex to Contigen. 17,18 Eighteen centers in the US and Canada will treat about 260 patients and each patient will be followed up for 12 months following treatment. Participants must be females over the age of 18 who have a history of SUI (for at least 12 months) and have failed prior non-invasive treatment (such as pelvic floor exercises and biofeedback), but have not received prior treatment with a bulking agent for SUI. Economic considerations: Health economic data for periurethral injection therapy is very limited. From the patient s perspective, pads are likely to be the major source of expenditure, so any treatment that reduces pad usage should provide substantial cost savings. From the perspective of the healthcare system, costs of materials used (e.g. slings or injectable agents), equipment required, type and duration of procedure, treatment of adverse effects, postoperative care, and the need for re-intervention in the case of insufficient efficacy are all important considerations. The objective of one economic analysis 19 was to investigate utility (patient preferences for given health states) with Zuidex therapy and to compare cost of Zuidex treatment with tension-free vaginal tape (TVT). Utility was measured using EuroQol (EQ-5D), a generic instrument. For the cost of Zuidex treatment, data was collected prospectively from participants in a 12 month open-label single-arm efficacy study 13 (n=82). Retrospective analysis of a comparable group of patients (n=77) with 3-6 months follow-up was used to obtain equivalent costs for TVT. Costs were analysed for both Sweden and France. Results indicated that injecting Zuidex via the implacer had lower overall costs than TVT (22,435 versus 28,954-32,019 Swedish krona per patient) while offering at least similar utility gain ( vs for TVT). Furthermore, Zuidex decreased pad usage by 58% over a 12 month period, translating into substantial savings for the patient over time. 19 The authors concluded that Zuidex Zuidex versus Contigen for stress urinary incontinence 5

6 could be considered at least as cost-effective as TVT, pending the availability of longterm effectiveness data. However, these results are limited by the fact that the study did not use a more robust method to compare the two treatment options. Another economic study evaluated the cost-effectiveness of surgery versus Contigen injection to treat female SUI after the failure of initial surgical treatment. 20 The analysis was conducted from the health care system perspectives of Ontario and Quebec. A decision-tree analysis was constructed to compare Contigen injection with three types of surgical procedures (retropubic suspension, transvaginal suspension, or sling). The incremental cost-effectiveness ratios to cure an additional patient with surgery ranged from C$ in Ontario and C$ in Quebec. The ratios were sensitive to changes in mean number of injections and a reduction in the length of hospital stay for surgery. The results suggested that while overall cost was lowest with Contigen, the lower likelihood of cure with this treatment made surgery more cost-effective as first-line therapy. The authors concluded that therapy with Contigen may be cost-effective as a follow-up treatment to surgical failure assuming the number of injections were minimized and post-surgery hospital stays were relatively lengthy. 20 Conclusions and implications for decision or policy making: In summary, the available evidence for Zuidex evaluation is very limited. Only low quality evidence from small short-term uncontrolled observational studies currently exists. Results indicate that Zuidex may be a promising alternative to surgery for SUI in those failing non-invasive therapies. Its efficacy in those who have not achieved symptom control with surgery is not yet clear. Similar to Contigen, some patients require multiple injections. While there is some long-term data, larger trials are needed to confirm the safety and efficacy of Zuidex. One potential advantage of Zuidex over Contigen includes the lack of a requirement for prior allergy skin testing. Furthermore, Zuidex can be administered without the need for endoscopic guidance. This reduces the level of equipment and facilities required for treatment, potentially increasing cost-effectiveness as well as convenience for the patient. Given current cost constraints, well designed randomized controlled trials comparing Zuidex with other treatment alternatives are required to fully assess clinical and economic benefit. Ultimately, cost-effectiveness should be confirmed with longerterm studies that account for treatment of complications and patients who eventually go on to receive more invasive surgery. Until higher quality evidence is available, the decision of when to use one injection bulking agent over another as an alternative to surgery must be based on costs specific to the particular institution and on clinical experience. Prepared by: Sarah Ndegwa, BScPharm, Research Officer Monika Mierzwinski-Urban, MLIS, Information Specialist Health Technology Inquiry Service htis@cadth.ca Tel: Zuidex versus Contigen for stress urinary incontinence 6

7 References: 1. Flesh G. Urinary incontinence with intrinsic sphinceter deficiency. In: UpToDate [database online]. Waltham (MA): UpToDate; DuBeau CE. Treatment of urinary incontinence. In: UpToDate [database online]. Waltham (MA): UpToDate; Kerr LA. Bulking agents in the treatment of stress urinary incontinence: history, outcomes, patient populations, and reimbursement profile. Rev Urol 2005;7 Suppl 1:S3-S11. Available: (accessed 2007 May 9). 4. Swanson JG, Kaczorowski J, Skelly J, Finkelstein M. Urinary incontinence: common problem among women over 45. Can Fam Physician 2005;51: Herschorn S. Current role of injectable agents for female stress urinary incontinence. Can J Urol 2006;13 Suppl 1: Zuidex system: a four point advantage for SUI. Uppsala, Sweden: Q-Med AB; Available: %20IFU% pdf (accessed 2007 May 9). 7. Fianu-Jonasson A, Edwall L, Wiberg MK. Magnetic resonance imaging to evaluate NASHA/Dx gel (Zuidex ) for stress urinary incontinence. Int J Clin Pract 2006;60(10): Pickard R, Reaper J, Wyness L, Cody DJ, McClinton S, N'Dow J. Periurethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2003;(2):CD Corcos J, Collet JP, Shapiro S, Herschorn S, Radomski SB, Schick E, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. Urology 2005;65(5): Stenberg A, Larsson G, Johnson P, Heimer G, Ulmsten U. DiHA Dextran Copolymer, a new biocompatible material for endoscopic treatment of stress incontinent women. Short term results. Acta Obstet Gynecol Scand 1999;78(5): Stenberg ÅM, Larsson G, Johnson P. Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer. Int Urogynecol J Pelvic Floor Dysfunct 2003;14(5): Zuidex versus Contigen for stress urinary incontinence 7

8 12. Van Kerrebroeck P, ter Meulen F, Larsson G, Farrelly E, Edwall L, Fianu-Jonasson A. Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence. Urology 2004;64(2): Chapple CR, Haab F, Cervigni M, Dannecker C, Fianu-Jonasson A, Sultan AH. An open, multicentre study of NASHA/Dx Gel (Zuidex ) for the treatment of stress urinary incontinence. Eur Urol 2005;48(3): Van Kerrebroeck P, ter Meulen F, Larsson G, Farrelly E, Edwall L, Fianu-Jonasson A. Treatment of stress urinary incontinence using a copolymer system: impact on quality of life. BJU Int 2004;94(7): Available: s= &dopt=abstract (accessed 2007 May 9). 15. Van Kerrebroeck P, Larsson G, Farrely E. The Zuidex system for the treatment of stress urinary incontinence: 24-month follow-up [abstract]. Joint Meeting of the International Continence Society and UroGynecological Association; 2004 Aug 23; Paris. Abstract no Castillo-Vico MT, Checa-Vizcaino MA, Payà-Panadés A, Rueda-García C, Carreras-Collado R. Periurethral granuloma following injection with dextranomer/hyaluronic acid copolymer for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(1):95-7. Available: (accessed 2007 May 10). 17. Appell RA, Boone TB, Smith CP. A randomized, evaluator-blinded, multi-center study comparing the efficacy and safety of ZUIDEX with Contigen in female patients with stress urinary incontinence. (Protocol #: 33DS0201; H-13639). Houston (TX): Baylor College of Medicine; Available: (accessed 2007 May 9). 18. Q-Med. Q-Med receives FDA approval to initiate the ZUIDEX clinical trial in the USA [press release]. Uppsala, Sweden: Q-Med AB; Available: (accessed 2007 May 10). 19. Kobelt G, Fianu-Jonasson A. Treatment of stress urinary incontinence with nonanimal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel: an analysis of utility and cost. Clin Drug Investig 2006;26(10): Oremus M, Collet JP, Shapiro SH, Penrod J, Corcos J. Surgery versus collagen for female stress urinary incontinence: economic assessment in Ontario and Quebec. Can J Urol 2003;10(4): } Zuidex versus Contigen for stress urinary incontinence 8

Medical Policy Title: Periurethral Bulking ARBenefits Approval: <Date>

Medical Policy Title: Periurethral Bulking ARBenefits Approval: <Date> Medical Policy Title: Periurethral Bulking ARBenefits Approval: Agents for the Treatment of Incontinence Effective Date: 01/01/2012 Document: ARB0279 Revision Date: Code(s): 51715 Endoscopic injection

More information

Periurethral Bulking Agents for the Treatment of Urinary Incontinence. Original Policy Date

Periurethral Bulking Agents for the Treatment of Urinary Incontinence. Original Policy Date MP 7.01.14 Periurethral Bulking Agents for the Treatment of Urinary Incontinence Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature

More information

MEDICAL POLICY SUBJECT: BULKING AGENTS FOR TREATMENT OF URINARY OR FECAL INCONTINENCE. POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: BULKING AGENTS FOR TREATMENT OF URINARY OR FECAL INCONTINENCE. POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: BULKING AGENTS FOR (ARCHIVED DATE: 05/28/09-, EDITED DATE: 05/27/10, 05/19/11, 05/24/12, 05/23/13) PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific

More information

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE FECAL INCONTINENCE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Urinary Incontinence. Biopolymer GmbH & Co.KG - Germany

Urinary Incontinence. Biopolymer GmbH & Co.KG - Germany Urinary Incontinence Treatment Options: 1. Physical Therapy: a conservative early stage treatment for UI, including pelvic floor muscles training known as Kegel exercise. 2. Medications: by means of pharmaceutical

More information

An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence

An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence European Urology European Urology 48 (2005) 488 494 Female UrologyöIncontinence An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence Christopher R. Chapple

More information

Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011

Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Treatment, Urinary Stress Incontinence, Transurethral Effective Date: 01/01/2012 Document: ARB0359 Revision Date: Code(s): 53860 Transurethral

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence: the management of urinary incontinence in women 1.1 Short title Urinary incontinence 2 Background a) The National

More information

Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence EFFECTIVE DATE:02 5 2013 POLICY LAST UPDATED: 12 18 2018 OVERVIEW Bulking agents are injectable substances

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Injectable Bulking Agents for the Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Injectable Bulking Agents for the Treatment of Urinary and

More information

A PATIENT GUIDE TO Understanding Stress Urinary Incontinence

A PATIENT GUIDE TO Understanding Stress Urinary Incontinence A PATIENT GUIDE TO Understanding Stress Urinary Incontinence Q: What is SUI? A: Stress urinary incontinence is defined as the involuntary leakage of urine. The problem afflicts approximately 18 million

More information

Operative Approach to Stress Incontinence. Goals of presentation. Preoperative evaluation: Urodynamic Testing? Michelle Y. Morrill, M.D.

Operative Approach to Stress Incontinence. Goals of presentation. Preoperative evaluation: Urodynamic Testing? Michelle Y. Morrill, M.D. Operative Approach to Stress Incontinence Goals of presentation Michelle Y. Morrill, M.D. Director of Urogynecology The Permanente Medical Group Kaiser, San Francisco Review preoperative care & evaluation

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal File Name: Origination: Last CAP Review: Next CAP Review: Last Review: injectable_bulking_agents_for_the_treatment_of_urinary_and_fecal_incontinence

More information

Medical Review Criteria Invasive Treatment for Urinary Incontinence

Medical Review Criteria Invasive Treatment for Urinary Incontinence Medical Review Criteria Invasive Treatment for Urinary Incontinence Effective Date: December 21, 2016 Subject: Invasive Treatment for Urinary Incontinence Background: Urinary incontinence (the involuntary

More information

MP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

MP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment of Urinary and

More information

Title: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines

Title: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines Title: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines Date: 16 June 2008 Context and policy issues: A metered

More information

TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness

TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness DATE: 21 November 2008 RESEARCH QUESTIONS: 1. What is the evidence for the clinical effectiveness of the 1g dose

More information

q7:480499_P0 6/5/09 10:23 AM Page 1 WHAT YOU SHOULD KNOW ABOUT YOUR DIAGNOSIS OF STRESS URINARY INCONTINENCE

q7:480499_P0 6/5/09 10:23 AM Page 1 WHAT YOU SHOULD KNOW ABOUT YOUR DIAGNOSIS OF STRESS URINARY INCONTINENCE 493495.q7:480499_P0 6/5/09 10:23 AM Page 1 WHAT YOU SHOULD KNOW ABOUT YOUR DIAGNOSIS OF STRESS URINARY INCONTINENCE 493495.q7:480499_P0 6/5/09 10:23 AM Page 2 What is Stress Urinary Incontinence? Urinary

More information

Sep \8958 Appell Dmochowski.ppt LMF 1

Sep \8958 Appell Dmochowski.ppt LMF 1 Surgical Outcomes (How did we get ourselves into this mess?) Roger R. Dmochowski, MD, FACS Department of Urologic Surgery Vanderbilt University School of Medicine Nashville, Tennessee Considerations Evaluation

More information

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2014 Origination: 2/1994 Next Review: 6/2015 Policy Blue Cross and Blue Shield of Kansas

More information

6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence

6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page Stress Urinary Incontinence - A Stressful Prospect

More information

Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review

Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in

More information

Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence 09-A9000-03 Original Effective Date: 02/15/12 Reviewed: 12/06/18 Revised: 12/15/18 Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence THIS MEDICAL COVERAGE GUIDELINE

More information

Clinical Policy: Urinary Incontinence Devices and Treatments

Clinical Policy: Urinary Incontinence Devices and Treatments Clinical Policy: Reference Number: CP.MP.142 Last Review Date: 03/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description

More information

Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566

Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Single-incision short sling mesh insertion for stress urinary incontinence in women Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Your responsibility This guidance

More information

TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness

TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness DATE: 24 November 2008 CONTEXT AND POLICY ISSUES: Urinary tract infections (UTI) are the

More information

Protocol. Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Protocol. Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Injectable Bulking Agents for the Treatment of Urinary and Fecal (70119) Medical Benefit Effective Date: 07/01/15 Next Review Date: 05/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11,

More information

TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety

TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety DATE: 1 April 2010 CONTEXT AND POLICY ISSUES: The prevalence of epilepsy ranges from 0.5% to 1%, 1,2 and

More information

Treatment Outcomes of Tension-free Vaginal Tape Insertion

Treatment Outcomes of Tension-free Vaginal Tape Insertion Are the Treatment Outcomes of Tension-free Vaginal Tape Insertion the Same for Patients with Stress Urinary Incontinence with or without Intrinsic Sphincter Deficiency? A Retrospective Study in Hong Kong

More information

Blue Ridge Urogynecology

Blue Ridge Urogynecology Surgery for Stress Urinary Incontinence Surgery has proved to be a very effective treatment for stress incontinence. The best surgical procedures improve or cure the incontinence in 85 to 90 percent of

More information

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Last Review Status/Date: September 2015 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances that used to increase tissue bulk. They can be injected periurethrally

More information

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2017 Origination: 2/1994 Next Review: 6/2018 Policy Blue Cross and Blue Shield of Kansas

More information

MP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

MP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Surgery End Date: 08/19/2018 Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment

More information

Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy #: 455 Latest Review Date: July 2014 Category: Surgery Policy Grade: B Background/Definitions: As a

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women

More information

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence 7.01.19 Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Section 7.0 Surgery Subsection Effective Date February 27, 2015 Original Policy Date February 27, 2015 Next Review

More information

Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS

Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama

More information

Surgery for stress incontinence:

Surgery for stress incontinence: Surgery for stress incontinence: information for you aashara Published February 2005 by the RCOG Contents Key points About this information What is stress incontinence? Do I need an operation? What operation

More information

Injectable Bulking Agents for the Treatment of Fecal Incontinence. Policy Specific Section: September 27, 2013 January 1, 2015

Injectable Bulking Agents for the Treatment of Fecal Incontinence. Policy Specific Section: September 27, 2013 January 1, 2015 Medical Policy Injectable Bulking Agents for the Treatment of Fecal Incontinence Type: Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date: September 27,

More information

Various Types. Ralph Boling, DO, FACOG

Various Types. Ralph Boling, DO, FACOG Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with

More information

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Last Review Status/Date: March 2017 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to

More information

Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence

Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,

More information

Bulkamid. Patient Information. Obstetrics & Gynaecology Department

Bulkamid. Patient Information. Obstetrics & Gynaecology Department Bulkamid Patient Information Obstetrics & Gynaecology Department Author ID: JD Leaflet Number: Gyn 050 Version: 5 Name of Leaflet: Bulkamid Date Produced: November 2017 Review Date: November 2019 Bulkamid

More information

What you should know about your diagnosis of incontinence

What you should know about your diagnosis of incontinence What you should know about your diagnosis of incontinence What is Stress Urinary Incontinence? WHAT IS NORMAL URINARY FUNCTION? Urine is a normal waste product of the body that is manufactured by the kidneys

More information

Stress Incontinence. Susannah Elvy Urogynaecology CNS

Stress Incontinence. Susannah Elvy Urogynaecology CNS Stress Incontinence Susannah Elvy Urogynaecology CNS Definitions Prevalence Assessment Investigation Treatment Surgery Men International Continence Society define as the complaint of any involuntary leakage

More information

Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents

Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents Abstract Andrew J. Steward Department of Aerospace and Mechanical Engineering University of Notre Dame, Notre Dame, IN

More information

TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines

TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines DATE: 5 May 2009 RESEARCH QUESTION: What recommendations exist for

More information

Injection of Urethral Bulking Agents

Injection of Urethral Bulking Agents Injection of Urethral Bulking Agents Department of Gynaecology Patient Information What are urethral bulking agents? Urethral bulking agents are substances that are injected to support the bladder neck.

More information

Loss of Bladder Control

Loss of Bladder Control BLADDER HEALTH: Surgery for Urinary Incontinence Loss of Bladder Control Surgery for Urinary Incontinence Don t Let Urinary Incontinence Keep You from Enjoying Life. What is Urinary Incontinence? What

More information

TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness

TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness DATE: 08 October 2009 CONTEXT AND POLICY ISSUES: Poly-drug abuse is

More information

TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness

TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness DATE: 14 October 2008 RESEARCH QUESTION: What are the clinical benefits and harms of using vacuum boards for spinal motion restriction?

More information

A minimally invasive treatment for stress urinary incontinence

A minimally invasive treatment for stress urinary incontinence A minimally invasive treatment for stress urinary incontinence This booklet provides information about the Bulkamid hydrogel for the treatment of stress urinary incontinence What is stress urinary incontinence?

More information

DATE: 17 July 2012 CONTEXT AND POLICY ISSUES

DATE: 17 July 2012 CONTEXT AND POLICY ISSUES TITLE: Sterile Pre-filled Saline Syringes for Acute Care Patients: A Review of Clinical Evidence, Cost-effectiveness, Evidence-based Guidelines, and Safety DATE: 17 July 2012 CONTEXT AND POLICY ISSUES

More information

TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness

TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness DATE: 27 August 2014 CONTEXT AND POLICY ISSUES Mental illness, including major depressive episode,

More information

Loss of Bladder Control

Loss of Bladder Control BLADDER HEALTH Loss of Bladder Control SURGERY TO TREAT URINARY INCONTINENCE AUA FOUNDATION OFFICIAL FOUNDATION OF THE AMERICAN UROLOGICAL ASSOCIATION What Is Urinary Incontinence? Urinary incontinence

More information

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES: TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY

More information

Urinary Incontinence for the Primary Care Provider

Urinary Incontinence for the Primary Care Provider Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,

More information

TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations

TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the

More information

Tension Free vaginal tape. Mrs Ami Shukla, Consultant Urogynaecologist Northampton General Hospital Northampton NN1 5BD

Tension Free vaginal tape. Mrs Ami Shukla, Consultant Urogynaecologist Northampton General Hospital Northampton NN1 5BD Tension Free vaginal tape Mrs Ami Shukla, Consultant Urogynaecologist Northampton General Hospital Northampton NN1 5BD What is a TVT procedure? A TVT (Tension Free Vaginal Tape) procedure is an operation

More information

Date: 23 June Context and policy issues:

Date: 23 June Context and policy issues: Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review

More information

TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness

TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness DATE: 19 November 2009 CONTEXT AND POLICY ISSUES: Autism is a pervasive developmental disorder characterized

More information

Urogynaecology. Colm McAlinden

Urogynaecology. Colm McAlinden Urogynaecology Colm McAlinden Definitions Urinary incontinence compliant of any involuntary leakage of urine with many different causes Two main types: Stress Urge Definitions Nocturia: More than a single

More information

Management of Female Stress Incontinence

Management of Female Stress Incontinence Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss

More information

TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines

TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines DATE: 11 August 2014 CONTEXT AND POLICY ISSUES Patient-controlled analgesia

More information

Title: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review

Title: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review Title: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review Date: 07 April 2008 Context and policy issues: Abdominal aortic aneurism (AAA)

More information

Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness

Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness Date: 28 May 2008 Research question: What is the evidence for the clinical effectiveness of a scoop stretcher to restrict

More information

I-STOP TOMS Transobturator Male Sling

I-STOP TOMS Transobturator Male Sling I-STOP TOMS Transobturator Male Sling The CL Medical I-STOP TOMS sling for male stress urinary incontinence was developed in France where it is widely used and is the market leader. It is constructed with

More information

W17: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October :00-18:00

W17: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October :00-18:00 W7: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October 204 4:00-8:00 Start End Topic Speakers 4:00 4:05 Introduction Sherif Mourad 4:05 4:20 Pathophysiology

More information

TITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines

TITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines TITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines DATE: 28 May 2009 RESEARCH QUESTIONS: 1. What is the clinical-effectiveness of tympanic, temporal, oral, and rectal thermometers

More information

Fecal Incontinence. Sphincter Augmentation. Alaiyan Bilal MD Hadassah mt scopus

Fecal Incontinence. Sphincter Augmentation. Alaiyan Bilal MD Hadassah mt scopus Fecal Incontinence Sphincter Augmentation Alaiyan Bilal MD Hadassah mt scopus AUGMENTATION METHODS Injectables( Bulking agents) Radiofrequency INJECTABLES Biomaterials Polytef, Autologous fat, GAX (glutaraldehyde

More information

Title: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition

Title: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition Title: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition Date: 15 May 2008 Context and policy issues: For patients who lose teeth due to various reasons, a fundamental

More information

Urinary Incontinence. Lora Keeling and Byron Neale

Urinary Incontinence. Lora Keeling and Byron Neale Urinary Incontinence Lora Keeling and Byron Neale Not life threatening. Introduction But can have a huge impact on quality of life. Two main types of urinary incontinence (UI). Stress UI leakage on effort,

More information

Tension-free Vaginal Tape for Urodynamic Stress Incontinence

Tension-free Vaginal Tape for Urodynamic Stress Incontinence Long-term Results of Tension-free Vaginal Tape Insertion for Urodynamic Stress Incontinence in Chinese Women at Eight-year Follow-up: a Prospective Study YM CHAN MBBS, MRCOG, FHKAM (O&G), DCG, DCH, DFM,

More information

TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines

TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines DATE: 08 May 2014 CONTEXT AND POLICY ISSUES Electroconvulsive therapy (ECT) is a treatment that

More information

Patient Information Leaflet

Patient Information Leaflet Patient Information Leaflet MID-URETHRAL SLING OPERATION TENSION-FREE VAGINAL TAPE (TVT) TRANSOBTURATOR TAPE (TOT, TVT-O) This information leaflet has been developed to help your understanding of what

More information

Advanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa

Advanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa Advanced Care for Female Overactive Bladder & Urinary Incontinence Department of Urology Kaiser Permanente Santa Rosa Goals Participants will: Review normal urinary tract anatomy and function Understand

More information

TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness

TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness DATE: 30 October 2008 RESEARCH QUESTION: What is the evidence for using memantine in combination

More information

Female Urinary Incontinence: What It Is and What You Can Do About It

Female Urinary Incontinence: What It Is and What You Can Do About It Female Urinary Incontinence: What It Is and What You Can Do About It Urogynecology Patient Information Sheet What is Urinary Incontinence? Stress Incontinence is a leakage of urine that occurs, for example,

More information

To compare intermittent catheterization, sling mobilization and sling transection for treatment of

To compare intermittent catheterization, sling mobilization and sling transection for treatment of 1 ABSTRACT: Objective: To compare intermittent catheterization, sling mobilization and sling transection for treatment of urinary retention after mid-urethral sling surgery. Methods: Data registered in

More information

Efficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study

Efficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study Efficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study Yvonne KY CHENG MBChB, MRCOG William WK TO MBBS, M Phil, FRCOG, FHKAM (O&G) HX

More information

This information is intended as an overview only

This information is intended as an overview only This information is intended as an overview only Please refer to the INSTRUCTIONS FOR USE included with this device for indications, contraindications, warnings, precautions and other important information

More information

TITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines

TITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines TITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines DATE: 21 July 2009 CONTEXT AND POLICY ISSUES: Pressure ulcers,

More information

BEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE. Urinary incontinence in women: the management of urinary incontinence in women

BEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE. Urinary incontinence in women: the management of urinary incontinence in women BEST PRACTICE ADVOCACY CENTRE NEW ZEALAND SCOPE 1 Guideline title Urinary incontinence in women: the management of urinary incontinence in women 2 Guideline Contextualisation This is a contextualisation

More information

03/13/18. A. Symptoms lasting for greater than or equal to 12 months that have resulted to significant impairment in activities of daily living; and

03/13/18. A. Symptoms lasting for greater than or equal to 12 months that have resulted to significant impairment in activities of daily living; and Reference #: MC/I008 Page: 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan

More information

Periurethral bulking injections for stress urinary incontinence

Periurethral bulking injections for stress urinary incontinence n The Leeds Teaching Hospitals NHS Trust Periurethral bulking injections for stress urinary incontinence Information for patients Leeds Centre for Women s Health Urinary incontinence is the involuntary

More information

DATE: 04 April 2012 CONTEXT AND POLICY ISSUES

DATE: 04 April 2012 CONTEXT AND POLICY ISSUES TITLE: Procedure Site Bleeding Complications Following Percutaneous Coronary Interventions or Angioplasty: A Review of Clinical Evidence and Guidelines DATE: 04 April 2012 CONTEXT AND POLICY ISSUES Percutaneous

More information

Gamal Ghoniem,*, Jacques Corcos, Craig Comiter, Peter Bernhard, O. Lenaine Westney and Sender Herschorn

Gamal Ghoniem,*, Jacques Corcos, Craig Comiter, Peter Bernhard, O. Lenaine Westney and Sender Herschorn Cross-Linked Polydimethylsiloxane Injection for Female Stress Urinary Incontinence: Results of a Multicenter, Randomized, Controlled, Single-Blind Study Gamal Ghoniem,*, Jacques Corcos, Craig Comiter,

More information

Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018

Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply

More information

Post- prostatectomy Incontinence - PPI

Post- prostatectomy Incontinence - PPI Post- prostatectomy Incontinence - PPI Dr. Kolombo Ivan, MD, FEBU Assoc.Prof. Popken Gralf MD, PhD, Assoc.Prof. Otčenášek Michal MD, PhD, Dr. Klézl Petr MD, MBA, Dr. Kolombová Jitka MD, MBA, Assoc.Prof.

More information

Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist

Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,

More information

A Case of Fecal Incontinence: Medical and Interventional Treatment Options

A Case of Fecal Incontinence: Medical and Interventional Treatment Options A Case of Fecal Incontinence: Medical and Interventional Treatment Options HPI JP is a 69 year-old F with a 12-month history of FI. Her symptoms began after a colonoscopy She has been experiencing passive

More information

Vaginal Tapes to Treat Stress Incontinence. Patient Information

Vaginal Tapes to Treat Stress Incontinence. Patient Information Vaginal Tapes to Treat Stress Incontinence Patient Information Author ID: JD Leaflet Number: Gyn 044 Version: 6 Name of Leaflet: Vaginal Tapes to Treat Stress Incontinence Date Produced: May 2017 Review

More information

Bard: Continence Therapy. Stress Urinary Incontinence. Regaining Control. Restoring Your Lifestyle.

Bard: Continence Therapy. Stress Urinary Incontinence. Regaining Control. Restoring Your Lifestyle. Bard: Continence Therapy Stress Urinary Incontinence Regaining Control. Restoring Your Lifestyle. Stress Urinary Incontinence Urinary incontinence is a common problem and one that can be resolved by working

More information

Urinary incontinence (UI) affects as many

Urinary incontinence (UI) affects as many EXPLORING NEW HORIZONS IN STRESS INCONTINENCE: THE NEUROUROLOGY CONNECTION W. Glenn Hurt, MD* ABSTRACT As many as one-third of women are affected by urinary incontinence, the most common of which being

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Vesicoureteral Reflux, Treatment with Periureteral Bulking Agents File Name: Origination: Last CAP Review: Next CAP Review: Last Review: vesicoureteral_reflux_treatment_with_periureteral_bulking_agents

More information

URINARY INCONTINENCE

URINARY INCONTINENCE Center for Continence Care and Pelvic Medicine What is urinary incontinence? URINARY INCONTINENCE Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Injectable Bulking Agents for Urinary Conditions and Fecal Incontinence Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information...

More information

Management of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital

Management of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence

More information

TITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness

TITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness TITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness DATE: 10 February 2009 CONTEXT AND POLICY ISSUES: Low back pain (LBP) is

More information

Glossary of terms Urinary Incontinence

Glossary of terms Urinary Incontinence Patient Information English Glossary of terms Urinary Incontinence Anaesthesia (general, spinal, or local) Before a procedure you will get medication to make sure that you don t feel pain. Under general

More information